| Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis |
SOUTH JORDAN, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the Wrapsody Cell-Impermeable Endoprosthesis (CIE) received regulatory approval from Health Canada. With this approval, Merit intends to begin immediate commercialization of the device throughout Canada with devices shipped from Merit's Toronto distribution center. |
globenewswire.com |
2025-05-06 13:25:00 |
Czytaj oryginał (ang.) |
| LH vs. MMSI: Which Stock Is the Better Value Option? |
Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Labcorp (LH) and Merit Medical (MMSI). But which of these two stocks offers value investors a better bang for their buck right now? |
zacks.com |
2025-05-05 16:46:15 |
Czytaj oryginał (ang.) |
| Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial |
In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months. In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months. |
globenewswire.com |
2025-05-05 13:25:00 |
Czytaj oryginał (ang.) |
| MMSI Stock Declines Despite Q1 Earnings Beating Estimates, Margins Up |
Merit Medical benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter of 2025. |
zacks.com |
2025-04-25 17:00:53 |
Czytaj oryginał (ang.) |
| Merit Medical Systems, Inc. (MMSI) Q1 2025 Earnings Call Transcript |
Merit Medical Systems, Inc. (NASDAQ:MMSI ) Q1 2025 Results Conference Call April 24, 2025 5:00 PM ET Company Participants Fred Lampropoulos - Founder, Chairman & Chief Executive Officer Raul Parra - Chief Financial Officer and Treasurer Brian Lloyd - Chief Legal Officer & Corporate Secretary Conference Call Participants Jason Bednar - Piper Sandler Steve Lichtman - Oppenheimer Robbie Marcus - J.P. Morgan Craig Bijou - Bank of America Securities David Rescott - Baird Michael Petusky - Barrington Research Jim Sidoti - Sidoti & Company Jon Young - Canaccord Mike Matson - Needham Jayson Bedford - Raymond James Operator Welcome to the Merit Medical Systems First Quarter 2025 Earnings Conference Call. |
seekingalpha.com |
2025-04-25 04:05:16 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Merit Medical (MMSI) Q1 Earnings: A Look at Key Metrics |
Although the revenue and EPS for Merit Medical (MMSI) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-04-24 23:05:45 |
Czytaj oryginał (ang.) |
| Merit Medical (MMSI) Q1 Earnings and Revenues Top Estimates |
Merit Medical (MMSI) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.77 per share a year ago. |
zacks.com |
2025-04-24 22:20:37 |
Czytaj oryginał (ang.) |
| What Analyst Projections for Key Metrics Reveal About Merit Medical (MMSI) Q1 Earnings |
Beyond analysts' top -and-bottom-line estimates for Merit Medical (MMSI), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025. |
zacks.com |
2025-04-21 14:22:05 |
Czytaj oryginał (ang.) |
| Will Merit Medical (MMSI) Beat Estimates Again in Its Next Earnings Report? |
Merit Medical (MMSI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2025-04-18 17:15:36 |
Czytaj oryginał (ang.) |
| Merit Medical (MMSI) Expected to Beat Earnings Estimates: Can the Stock Move Higher? |
Merit Medical (MMSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-17 15:06:04 |
Czytaj oryginał (ang.) |
| Merit Medical Stock Slips Despite the Launch of New Ventrax System |
MMSI launches the Ventrax Delivery System, enhancing pulmonary access procedures with improved control, precision, and efficiency for interventionalists. |
zacks.com |
2025-04-15 16:05:33 |
Czytaj oryginał (ang.) |
| 4 Stocks to Watch as Dental Supplies Recovers Amid Tariff Headwind |
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are CAH, MMSI, XRAY and CNMD. |
zacks.com |
2025-04-14 15:10:45 |
Czytaj oryginał (ang.) |
| Merit Medical (MMSI) Surges 8.3%: Is This an Indication of Further Gains? |
Merit Medical (MMSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2025-04-10 16:35:43 |
Czytaj oryginał (ang.) |
| Merit Medical Launches the Ventrax™ Delivery System |
Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardia Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardia |
globenewswire.com |
2025-04-09 13:25:00 |
Czytaj oryginał (ang.) |
| ALGN or MMSI: Which Is the Better Value Stock Right Now? |
Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Align Technology (ALGN) and Merit Medical (MMSI). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2025-04-08 16:45:35 |
Czytaj oryginał (ang.) |
| Merit Medical Systems to Announce First Quarter 2025 Results on April 24, 2025 |
SOUTH JORDAN, Utah, April 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2025, after the close of the stock market on Thursday, April 24, 2025. Merit plans to hold its investor conference call on the same day (Thursday, April 24, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). |
globenewswire.com |
2025-04-07 21:10:00 |
Czytaj oryginał (ang.) |
| Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now |
Merit Medical's strong product portfolio raises optimism about the stock. |
zacks.com |
2025-04-01 12:25:41 |
Czytaj oryginał (ang.) |
| Updated ASGE Clinical Practice Guideline Includes TIF 2.0 and cTIF for Management of GERD |
Endoscopic anti-reflux therapy recognized as evidence-based approach to providing relief of GERD symptoms. Endoscopic anti-reflux therapy recognized as evidence-based approach to providing relief of GERD symptoms. |
globenewswire.com |
2025-03-27 11:25:00 |
Czytaj oryginał (ang.) |
| Merit Medical Stock May Rise as WRAPSODY CIE Shows Strong Results |
MMSI unveils 12-month efficacy data for WRAPSODY CIE, highlighting its advanced technology in vascular access maintenance and potential to improve patient outcomes. |
zacks.com |
2025-03-26 13:40:28 |
Czytaj oryginał (ang.) |
| Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) |
SOUTH JORDAN, Utah, March 25, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial are scheduled for publication in the April issue of Kidney International . Twelve-month results from the randomized arm of the WAVE trial are scheduled for presentation at the Society of Interventional Radiology's 50th Annual Scientific Meeting in Nashville, TN. The podium presentation is scheduled for March 30, 2025, during the late-breaking trials session. |
globenewswire.com |
2025-03-25 11:25:00 |
Czytaj oryginał (ang.) |
| Merit Medical Systems, Inc. (MMSI) Q4 2024 Earnings Call Transcript |
Merit Medical Systems, Inc. (MMSI) Q4 2024 Earnings Call Transcript |
seekingalpha.com |
2025-02-26 00:39:03 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Merit Medical (MMSI) Q4 Earnings: A Look at Key Metrics |
While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-02-25 21:35:25 |
Czytaj oryginał (ang.) |
| Merit Medical (MMSI) Beats Q4 Earnings and Revenue Estimates |
Merit Medical (MMSI) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.81 per share a year ago. |
zacks.com |
2025-02-25 20:56:09 |
Czytaj oryginał (ang.) |
| Merit Medical Reports Fourth Quarter and Full Year 2024 Results and Issues Fiscal Year 2025 Guidance |
Fourth Quarter Highlights† Reported revenue of $355.2 million, up 9.4% Constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectively GAAP operating margin of 10.3%, compared to 10.4% in prior year period Non-GAAP operating margin* of 19.6%, compared to 16.6% in prior year period GAAP EPS $0.46, down 2.6%, Non-GAAP EPS* $0.93, up 25.8%, and Free cash flow* generation of $65.3 million, up 18.4% Fiscal Year 2024 Highlights† Reported revenue of $1.357 billion, up 7.9% Constant currency revenue* and constant currency revenue, organic* up 8.5% and up 6.0%, respectively GAAP operating margin of 11.5 %, compared to 9.9% in prior year Non-GAAP operating margin* of 19.0%, compared to 17.2% in prior year GAAP EPS $2.03, up 25.3%, Non-GAAP EPS* $3.46, up 21.3%, and Free cash flow* generation of $185.7 million, up 67.5% Fourth Quarter Business Developments Completed the acquisition of lead management portfolio of medical devices and certain related assets from Cook Medical Holdings, LLC Announced FDA premarket approval of the Wrapsody® Cell-Impermeable Endoprosthesis device, which is intended to extend long-term vessel patency in dialysis patients Substantially completed integration of the production, distribution and sale of the EsophyX® Z+ device previously acquired from Endogastric Solutions, Inc. Fiscal Year 2025 Guidance Revenue of $1.470 billion to $1.490 billion, up 8% - 10% year-over-year Non-GAAP EPS of $3.58 to $3.70, up 4% - 7% year-over-year † Comparisons noted in the bullet points are calculated for the current quarter compared with the fourth quarter of 2023 or for the current year compared with fiscal year 2023, as applicable, unless otherwise specified. Amounts in this release are rounded while percentages are calculated from the underlying amounts. |
globenewswire.com |
2025-02-25 18:05:00 |
Czytaj oryginał (ang.) |
| Gear Up for Merit Medical (MMSI) Q4 Earnings: Wall Street Estimates for Key Metrics |
Evaluate the expected performance of Merit Medical (MMSI) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. |
zacks.com |
2025-02-24 12:21:49 |
Czytaj oryginał (ang.) |
| Here is Why Growth Investors Should Buy Merit Medical (MMSI) Now |
Merit Medical (MMSI) could produce exceptional returns because of its solid growth attributes. |
zacks.com |
2025-02-21 15:45:24 |
Czytaj oryginał (ang.) |
| Here's Why Merit Medical (MMSI) is a Strong Momentum Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-02-07 12:51:18 |
Czytaj oryginał (ang.) |
| Looking for a Growth Stock? 3 Reasons Why Merit Medical (MMSI) is a Solid Choice |
Merit Medical (MMSI) possesses solid growth attributes, which could help it handily outperform the market. |
zacks.com |
2025-02-05 15:45:34 |
Czytaj oryginał (ang.) |
| Here's Why Merit Medical (MMSI) is a Strong Growth Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-02-03 12:46:14 |
Czytaj oryginał (ang.) |
| Will Merit Medical (MMSI) Beat Estimates Again in Its Next Earnings Report? |
Merit Medical (MMSI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2025-01-29 15:11:27 |
Czytaj oryginał (ang.) |
| Merit Medical Systems, Inc. (MMSI) Hits Fresh High: Is There Still Room to Run? |
Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2025-01-29 12:16:25 |
Czytaj oryginał (ang.) |
| Here's Why Merit Medical (MMSI) is a Strong Momentum Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-01-22 12:50:35 |
Czytaj oryginał (ang.) |
| 3 Reasons Why Growth Investors Shouldn't Overlook Merit Medical (MMSI) |
Merit Medical (MMSI) could produce exceptional returns because of its solid growth attributes. |
zacks.com |
2025-01-20 15:46:07 |
Czytaj oryginał (ang.) |
| BDX or MMSI: Which Is the Better Value Stock Right Now? |
Investors interested in Medical - Dental Supplies stocks are likely familiar with Becton Dickinson (BDX) and Merit Medical (MMSI). But which of these two stocks offers value investors a better bang for their buck right now? |
zacks.com |
2025-01-17 14:41:14 |
Czytaj oryginał (ang.) |
| Here's Why Merit Medical (MMSI) is a Strong Growth Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-01-17 12:46:16 |
Czytaj oryginał (ang.) |
| Merit Medical Stock Gains Following Solid Preliminary Q4 Revenues |
MMSI's revenue growth in the fourth quarter is likely to have been boosted by continued robust adoption of its products. |
zacks.com |
2025-01-15 13:36:11 |
Czytaj oryginał (ang.) |
| Merit Medical Announces Preliminary Unaudited Revenue for the Year Ended December 31, 2024 and Plans to Announce Fourth Quarter and Year End 2024 Results and Issue Fiscal Year 2025 Guidance on February 25, 2025 |
* Constant currency revenue is a non-GAAP financial measure. A reconciliation of this financial measure to its most directly comparable GAAP financial measure is included under the heading “Non-GAAP Financial Measure” below. |
globenewswire.com |
2025-01-13 21:10:00 |
Czytaj oryginał (ang.) |
| Is Merit Medical (MMSI) a Solid Growth Stock? 3 Reasons to Think "Yes" |
Merit Medical (MMSI) is well positioned to outperform the market, as it exhibits above-average growth in financials. |
zacks.com |
2025-01-02 15:54:37 |
Czytaj oryginał (ang.) |
| Here's Why You Should Add MMSI Stock to Your Portfolio Now |
Merit Medical's strong product portfolio raises optimism about the stock. |
zacks.com |
2025-01-02 14:20:28 |
Czytaj oryginał (ang.) |
| BDX vs. MMSI: Which Stock Is the Better Value Option? |
Investors interested in Medical - Dental Supplies stocks are likely familiar with Becton Dickinson (BDX) and Merit Medical (MMSI). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2025-01-01 14:51:07 |
Czytaj oryginał (ang.) |
| Here's Why Merit Medical (MMSI) is a Strong Growth Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-01-01 12:51:16 |
Czytaj oryginał (ang.) |
| Merit Medical Stock Rises Following FDA Nod for WRAPSODY Device |
MMSI announces FDA approval for the WRAPSODY Cell-Impermeable Endoprosthesis. |
zacks.com |
2024-12-23 14:31:07 |
Czytaj oryginał (ang.) |
| Merit Medical Announces FDA Approval of the WRAPSODY Cell-Impermeable Endoprosthesis |
SOUTH JORDAN, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that the WRAPSODY® Cell-Impermeable Endoprosthesis has received premarket approval from the US Food and Drug Administration (FDA). With this approval, Merit can begin commercialization of the device in the USA in 2025. |
globenewswire.com |
2024-12-20 11:15:00 |
Czytaj oryginał (ang.) |
| Merit Medical Announces Resignation of President, Joseph Wright |
SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI) (“Merit” or the “Company”), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025. |
globenewswire.com |
2024-12-16 18:00:00 |
Czytaj oryginał (ang.) |
| Why Merit Medical (MMSI) is a Top Growth Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-12-16 12:46:37 |
Czytaj oryginał (ang.) |
| Zacks Industry Outlook Becton, Dickinson, BD, McKesson, Cardinal Health and Merit Medical Systems |
Becton, Dickinson, BD, McKesson, Cardinal Health and Merit Medical Systems have been highlighted in this Industry Outlook article. |
zacks.com |
2024-12-13 05:15:24 |
Czytaj oryginał (ang.) |
| 4 Stocks to Watch Amid Dental Supplies Industry Challenges |
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are BDX, MCK, CAH and MMSI. |
zacks.com |
2024-12-12 11:46:09 |
Czytaj oryginał (ang.) |
| MMSI or WST: Which Is the Better Value Stock Right Now? |
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Merit Medical (MMSI) or West Pharmaceutical Services (WST). But which of these two stocks presents investors with the better value opportunity right now? |
zacks.com |
2024-11-29 14:46:27 |
Czytaj oryginał (ang.) |
| MMSI Stock Down Despite Latest Positive Data From WRAPSODY WAVE Trial |
The significant improvement in patency rates for AVG patients via Merit Medical's WRAPSODY device is expected to enhance patients' vascular access survival. |
zacks.com |
2024-11-26 14:06:21 |
Czytaj oryginał (ang.) |
| Fundus Camera Market Global Forecasts and Company Analysis 2025-2033, Profiles of Carl Zeiss Medites, Topcon Medical Systems, Merit Medical Systems, NIDEK, and Revenio Group |
Dublin, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The "Fundus Camera Market Global Forecast Report by Product Type, End-User, Countries and Company Analysis 2025-2033" report has been added to ResearchAndMarkets.com's offering. The Fundus Camera market was valued at US$459.40 million in 2024 and is anticipated to hit US$665.85 million by 2033 from 2025 to 2033 with a compound annual growth rate of 4.21%. The primary reason for this growth stems from the demand for more developed diagnostics within the eyes, mainly because of retinal disorders that have been on the rise across the globe. A fundus camera is a medical imaging device specific in the application of ophthalmology to capture high resolution images of the internal eye, with emphasis on the retina, optic disc, and macula. It illuminates and photographs the retina through the pupil to provide critical details necessary for diagnostics and management procedures in various eye conditions. Fundus cameras thus play an instrumental role in detecting retinal disorders including diabetic retinopathy, glaucoma, age-related macular degeneration, and retinal detachment. These conditions often progress in a gradual manner but may go unnoticed until they start impairing vision seriously. In that case, early detection via the use of fundus photography will give time to intervene before more serious vision loss takes place. There are mydriatic, non-mydratic, and hybrid types available, and there are also handheld or portable types for easier access. Apart from diagnosis, follow up of disease progression and effectiveness of the treatment being provided makes fundus imaging a tool more essential in eye care. Growth Drivers for the Fundus Camera Market |
globenewswire.com |
2024-11-25 12:25:00 |
Czytaj oryginał (ang.) |
| Merit Medical's WRAPSODY WAVE Trial Exceeds Performance Goals for Arteriovenous Graft (AVG) Patients |
WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial |
globenewswire.com |
2024-11-25 11:15:00 |
Czytaj oryginał (ang.) |
| 3 Reasons Why Growth Investors Shouldn't Overlook Merit Medical (MMSI) |
Merit Medical (MMSI) could produce exceptional returns because of its solid growth attributes. |
zacks.com |
2024-11-21 15:46:13 |
Czytaj oryginał (ang.) |
| Merit Medical Stock Gains 37.9% Year to Date: What's Behind the Rally? |
MMSI shows strong growth momentum with a robust product portfolio and recent acquisitions, positioning itself well in competitive healthcare markets. |
zacks.com |
2024-11-20 11:05:18 |
Czytaj oryginał (ang.) |
| Merit Medical Systems, Inc. (MMSI) Hits Fresh High: Is There Still Room to Run? |
Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2024-11-08 12:16:54 |
Czytaj oryginał (ang.) |
| BDX or MMSI: Which Is the Better Value Stock Right Now? |
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Becton Dickinson (BDX) or Merit Medical (MMSI). But which of these two stocks offers value investors a better bang for their buck right now? |
zacks.com |
2024-11-07 14:40:36 |
Czytaj oryginał (ang.) |
| Is Merit Medical (MMSI) a Solid Growth Stock? 3 Reasons to Think "Yes" |
Merit Medical (MMSI) possesses solid growth attributes, which could help it handily outperform the market. |
zacks.com |
2024-11-05 15:46:31 |
Czytaj oryginał (ang.) |
| Why Merit Medical (MMSI) is a Top Momentum Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-11-01 12:50:16 |
Czytaj oryginał (ang.) |